Cancer Research, Statistics, and Treatment最新文献_第2页

Pink ribbon 粉红丝带

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_11_23

K. Patro, A. Avinash

引用次数: 0

A narrative review of particle therapy in cancer 肿瘤粒子治疗的叙述性回顾

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_272_22

Mayakannan Krishnan, C. Ranjith

{"title":"A narrative review of particle therapy in cancer","authors":"Mayakannan Krishnan, C. Ranjith","doi":"10.4103/crst.crst_272_22","DOIUrl":"https://doi.org/10.4103/crst.crst_272_22","url":null,"abstract":"The use of high-energy charged particles in radiotherapy has evolved into an advanced cancer treatment. Even though proton beams and carbon ions are currently the popular particles used for radiotherapy in cancer, ions such as pions, helium, argon, and neon were previously used. To prepare this article, reviewed the literature relevant to the history, current status, and clinical outcomes of particle therapy for specific types of tumors by searching in PubMed and Google Scholar using specific search terms. This article reviews the history, current status, physics, and radiobiological advantages of particle therapy. Outcomes of particle therapy for sites such as the head-and-neck, central nervous system, lung, and prostate have been discussed. The physical and biological properties of particle therapy have been shown to be effective in reducing radiation-induced acute toxicities to a large extent as well as reducing the integral dose, i.e., the sum of dose delivered at every point in a patient's body, multiplied by the volume of tissue at each point and then added up over the entire treated volume. It is used to assess the potential risks associated with radiation therapy. The advantages of particle therapy over conventional photon therapy in terms of overall survival and local control rates have been described. Advances in image guidance and newer particle acceleration technologies have improved the efficiency of particle therapy treatment.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90636811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ChatGPT in the current form is not ready for unaudited use in healthcare and scientific research 目前形式的ChatGPT还不能在医疗保健和科学研究中未经审核地使用

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_144_23

Raju Vaishya, S. Kambhampati, K. Iyengar, A. Vaish

引用次数: 1

To look beyond attaining a cure in Hodgkin's lymphoma 不只是为了治愈霍奇金淋巴瘤

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_162_23

S. Vaniyath

引用次数: 0

Authors' reply to Sabu et al. 作者对Sabu等人的回复。

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_195_23

Vijeta Bajpai, A. Batra, Rahul Sarode

引用次数: 0

Democratizing scientific and healthcare communication with large language models 使用大型语言模型实现科学和医疗保健交流的民主化

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_157_23

Tejas S. Sathe, Madelyn A. Flitcroft, A. Kothari

引用次数: 2

Can intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) replace consolidation brachytherapy in the curative treatment of cervical cancer? A dosimetric study 同步综合增强调强放疗(IMRT-SIB)能否取代近距离巩固放疗在宫颈癌的根治性治疗中?剂量学研究

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_107_23

Raphel Naorem, Kalichamy Rangasamy, Kshitish Ghogale, Chaitali Waghmare

引用次数: 0

Irreversible bilateral optic neuropathy from gemcitabine-oxaliplatin combination chemotherapy: A case report 吉西他滨-奥沙利铂联合化疗引起的不可逆双侧视神经病变1例

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_18_23

P. Chatterjee, Reshmi Dasgupta, Biplab Sarkar

引用次数: 1

Amivantamab: A narrative drug review 阿米万他抗:叙述性药物回顾

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_166_23

Anupa John, V. Noronha, Ajay Singh, N. Nandini Menon, K. Prabhash

{"title":"Amivantamab: A narrative drug review","authors":"Anupa John, V. Noronha, Ajay Singh, N. Nandini Menon, K. Prabhash","doi":"10.4103/crst.crst_166_23","DOIUrl":"https://doi.org/10.4103/crst.crst_166_23","url":null,"abstract":"Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an altered active site that sterically interferes with tyrosine kinase inhibitor (TKI) binding, resulting in a poorer response rate to EGFR TKIs. Amivantamab (JNJ-61186372), a fully humanized EGFR- mesenchymal-epithelial transition receptor (MET) bispecific antibody has been approved for use in adults with locally advanced or metastatic NSCLC with EGFR Ex20Ins mutations, whose disease has progressed on or after platinum-based chemotherapy. To prepare this review, we searched various websites, including the European Medicines Agency Drug Manual, United States Food and Drug Administration, PubMed, Science Direct, and UpToDate using the search terms, “Amivantamab,” “NJ-61186372,” “amivantamab-vmjw,” and” “EGFRexon20ins.” We shortlisted 121 articles published between 2015 and 2023, of which 49 were included. This review discusses the clinical indications, adverse effects, safety, pharmacodynamics, pharmacokinetics, and the key research trials that investigated the use of amivantamab.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80041556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Patient with cancer who found support and care from ChatGPT 从ChatGPT获得支持和关怀的癌症患者

Cancer Research, Statistics, and Treatment Pub Date : 2023-04-01 DOI: 10.4103/crst.crst_113_23

Sunny Chi Lik Au

引用次数: 0